Malaria vaccine - Apovia
Alternative Names: ICC 1132; MalariVax™Latest Information Update: 24 Oct 2021
Price :
$50 *
At a glance
- Originator Apovia (CEASED)
- Developer Malaria Vaccine Initiative
- Class Parasitic vaccines; Virus-like particle vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Malaria
Most Recent Events
- 18 Feb 2005 A clinical study has been added to the Parasitic infections immunogenicity section
- 16 Dec 2003 Data presented at the 52nd Annual Meeting of the American Society of Tropical Medicine and Hygiene (ASTMH-2003) have been added to the Parasitic Infections immunogenicity section
- 03 Dec 2003 A phase I trial has been completed for Malaria in Germany